The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The immune system and COVID-19: Friend or foe?
Open accessAbstract
Aim Coronavirus disease 2019 (COVID-19) is a novel highly contagious infection caused by SARS-CoV-2, which has been became a global public health challenge. The pathogenesis of this virus is not yet clearly understood, but there is evidence of a hyper-inflammatory immune response in critically ill patients, which leads to acute respiratory distress syndrome (ARDS) and multi-organ failure. Material and methods A literature review was performed to identify relevant articles on COVID-19 published up to April 30, 2020. The search resulted in 361 total articles. After reviewing the titles and abstracts for inclusion, some irrelevant papers were excluded. Additional relevant articles were identified from a review of citations referenced. Key findings SARS-CoV-2, directly and indirectly, affects the immune system and avoids being eliminated in early stages. On the other hand, the secretion of inflammatory cytokines creates critical conditions that lead to multi-organ failure. Significance The immune system which is affected by the virus tries to respond via a cytokine storm and hyperinflammation, which itself leads to further multi-organ damage and even death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.006 · Cited by 2,219
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“Moreover, IL-6 decreases the expression of HLA-DR on the membrane and production of IFN-γ by CD4 cells [4].”
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Coronavirus infections and immune responses
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25685 · Cited by 1,946
Zhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758
Molecular immune pathogenesis and diagnosis of COVID-19
Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.001 · Cited by 1,721
Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102763 · Cited by 1,702
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J.-Q., Du, P., Wei, D., Zhang, Y., Sun, X.-X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,593
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Barnes, B. J., Adrover, J. M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J. M., Daßler-Plenker, J., Guerci, P., Huynh, C., Knight, J. S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200652 · Cited by 1,486
Diabetes is a risk factor for the progression and prognosis of COVID‐19
Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., Du, K., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3319 · Cited by 1,404
Cutaneous manifestations in COVID‐19: a first perspective
Recalcati, S. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16387 · Cited by 1,348
A human monoclonal antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B.-J. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,132
Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes
Yang, J.-K., Lin, S.-S., Ji, X.-J., & Guo, L.-M. (2010) · Acta Diabetologica · doi:10.1007/s00592-009-0109-4 · Cited by 1,084
Jia, H. P., Look, D. C., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane, C., Perlman, S., & McCray, P. B. (2005) · Journal of Virology · doi:10.1128/jvi.79.23.14614-14621.2005 · Cited by 949
Lin, L., Lu, L., Cao, W., & Li, T. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1746199 · Cited by 914
Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review
Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082690 · Cited by 822
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Wu, D., & Yang, X. O. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.005 · Cited by 785
Liu, B., Li, M., Zhou, Z., Guan, X., & Xiang, Y. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102452 · Cited by 763
Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Kirkpatrick, E., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 649
On the Alert for Cytokine Storm: Immunopathology in COVID‐19
Henderson, L. A., Canna, S. W., Schulert, G. S., Volpi, S., Lee, P. Y., Kernan, K. F., Caricchio, R., Mahmud, S., Hazen, M. M., Halyabar, O., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41285 · Cited by 633
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
Russell, B., Moss, C., George, G., Santaolalla, A., Cope, A., Papa, S., & Van Hemelrijck, M. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1022 · Cited by 439
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Ulrich, H., & Pillat, M. M. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-09976-7 · Cited by 418
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., & Lv, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25882 · Cited by 410
Wang, X., Fang, X., Cai, Z., Wu, X., Gao, X., Min, J., & Wang, F. (2020) · Research · doi:10.34133/2020/2402961 · Cited by 387
Fung, S.-Y., Yuen, K.-S., Ye, Z.-W., Chan, C.-P., & Jin, D.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1736644 · Cited by 381
Lymphopenia in COVID‐19: Therapeutic opportunities
Fathi, N., & Rezaei, N. (2020) · Cell Biology International · doi:10.1002/cbin.11403 · Cited by 324
Self-citationWan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16659 · Cited by 309
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
Roback, J. D., & Guarner, J. (2020) · JAMA · doi:10.1001/jama.2020.4940 · Cited by 299
Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19
Li, G., He, X., Zhang, L., Ran, Q., Wang, J., Xiong, A., Wu, D., Chen, F., Sun, J., & Chang, C. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102463 · Cited by 290
Progress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 282
Immune-epidemiological parameters of the novel coronavirus – a perspective
Saghazadeh, A., & Rezaei, N. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1750954 · Cited by 223
Self-citationRokni, M., Ghasemi, V., & Tavakoli, Z. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2107 · Cited by 219
Gianfrancesco, M. A., Hyrich, K. L., Gossec, L., Strangfeld, A., Carmona, L., Mateus, E. F., Sufka, P., Grainger, R., Wallace, Z., Bhana, S., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30095-3 · Cited by 212
Jawhara, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072272 · Cited by 163
Saghazadeh, A., & Rezaei, N. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106560 · Cited by 162
Self-citationMeshkani, R., & Vakili, S. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.08.015 · Cited by 149
Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.
Infantino, M. G., Damiani, A., Gobbi, F. L., Grossi, V., Lari, B., Macchia, D., Casprini, P., Veneziani, F., Villalta, D., Bizzaro, N., et al. (2020) · PubMed · Cited by 146
CoViD-19 Immunopathology & Immunotherapy
Chiappelli, F., Khakshooy, A., & Greenberg, G. (2020) · Bioinformation · doi:10.6026/97320630016219 · Cited by 132
Vascular pharmacology of acute lung injury and acute respiratory distress syndrome
Groeneveld, A. B. J. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00013-2 · Cited by 119
Current Drugs with Potential for Treatment of COVID-19: A Literature Review
Rabby, M. I. I. (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31002 · Cited by 117
Borderless collaboration is needed for COVID-19—A disease that knows no borders
Mohamed, K., Rodríguez‐Román, E., Rahmani, F., Zhang, H., Ivanovska, M., Makka, S. A., Joya, M., Makuku, R., Islam, M. S., Radwan, N. M., et al. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.162 · Cited by 94
Self-citationCOVID-19 affects healthy pediatricians more than pediatric patients
Rezaei, N. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.139 · Cited by 62
Self-citation[Cells of innate and adaptive immunity in type 2 diabetes and obesity].
Guzmán‐Flores, J. M., & López-Briones, S. (2012) · PubMed · Cited by 50
Can an effective SARS-CoV-2 vaccine be developed for the older population?
Pawelec, G., & Weng, N. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00180-2 · Cited by 50
Central Nervous System Involvement in COVID-19
Jahanshahlu, L., & Rezaei, N. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.05.016 · Cited by 50
Self-citationBenign COVID-19 in an immunocompromised cancer patient – the case of a married couple
Spezzani, V., Piunno, A., & Iselin, H.-U. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20246 · Cited by 44
Cited by
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
Role of Toll‐like receptors in the pathogenesis of COVID‐19
Khanmohammadi, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26826 · Cited by 370
Self-citationJafarzadeh, A., Chauhan, P., Saha, B., Jafarzadeh, S., & Nemati, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118102 · Cited by 327
COVID-19: Poor outcomes in patients with zinc deficiency
Jothimani, D., Kailasam, E., Danielraj, S., Nallathambi, B., Ramachandran, H., Sekar, P., Manoharan, S., Ramani, V., Narasimhan, G., Kaliamoorthy, I., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.014 · Cited by 296
de Lima Beltrão, F. E., de Almeida Beltrão, D. C., Carvalhal, G., de Lima Beltrão, F. E., de Souza Braga Filho, J., de Brito Oliveira, J., de Jesus, J. D. S., Machado, G. J. R., dos Santos Silva, H., Teixeira, H. M. P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac075 · Cited by 12
Metadata
- Authors
- Yazdanpanah, F., Hamblin, M. R., & Rezaei, N.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 256
- Pages
- 117900
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3031723755
- Cited by
- 270
- References
- 55
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.